Fig A1. Best change in sum of the longest diameters (SLD) from baseline by cohort, on the basis of an independent review facility assessment. (A) Cohort 1 (1L), (B) cohort 2 (2L), and (C) cohort 3 (3L). Complete responders are indicated in blue, partial responders in gold, patients with stable disease in red, and patients experiencing disease progression in gray. aPatients with TC3 or IC3 PD-L1 immunohistochemistry status. On the basis of a data cutoff of December 1, 2015. 1L, first line; 2L, second line; 3L, third line; IC, tumor-infiltrating immune cells; PD-L1, programmed death-ligand 1; TC, tumor cells; TC3 or IC3 = TC 50% or IC 10% PD-L1–expressing cells, respectively.